Neurocrine Biosciences traded at $86.75 this Wednesday May 25th, increasing $2.15 or 2.54 percent since the previous trading session. Looking back, over the last four weeks, Neurocrine Biosciences gained 7.48 percent. Over the last 12 months, its price fell by 10.19 percent. Looking ahead, we forecast Neurocrine Biosciences to be priced at 83.82 by the end of this quarter and at 77.76 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
86.75
Daily Change
2.54%
Yearly
-10.19%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 151.14 2.02 1.35% 31.77%
Acadia Pharmaceuticals 15.94 -0.04 -0.25% -25.09%
Acorda Therapeutics 0.42 -0.02 -4.09% -88.74%
Agios Pharmaceuticals 19.34 -0.13 -0.67% -65.65%
ALKERMES 28.70 0.35 1.23% 32.93%
Alnylam Pharmaceuticals 125.65 -1.40 -1.10% -9.86%
Amgen 250.98 -0.91 -0.36% 5.21%
Aptinyx Inc 0.52 -0.04 -7.59% -80.15%
Biogen 198.93 -3.62 -1.78% -25.73%
BioMarin Pharmaceutical 78.79 0.01 0.01% 1.95%
Cytokinetics 38.99 0.75 1.96% 74.61%
Dynavax Technologies 11.23 -0.05 -0.44% 47.18%
Enanta Pharmaceuticals 39.10 -0.13 -0.33% -18.83%
Exelixis 17.86 0.16 0.90% -20.13%
Gilead Sciences 64.25 -0.10 -0.15% -3.16%
Halozyme Therapeutics 45.09 0.27 0.60% 6.77%
Intercept Pharmaceuticals 16.86 0.24 1.44% 9.06%
Incyte Corp 75.78 0.67 0.89% -8.87%
Ionis Pharmaceuticals 37.19 0.08 0.22% 5.41%
Intra Cellular Therapies 56.20 -0.76 -1.33% 46.66%
Neurocrine Biosciences 86.75 2.15 2.54% -10.19%
Nektar Therapeutics 3.39 0 0% -80.71%
Pfizer 53.28 -0.14 -0.25% 36.88%
Prothena 25.70 -0.25 -0.96% -3.60%
Ultragenyx Pharmaceutical 45.79 -0.02 -0.03% -55.51%
Regeneron Pharmaceuticals 688.36 2.34 0.34% 38.46%
Repligen 150.99 -0.44 -0.29% -15.61%
Rigel Pharmaceuticals 1.86 0.01 0.54% -47.90%
Sarepta Therapeutics 69.22 0.38 0.55% -7.83%
Teva Pharmaceutical Industries Ltd 2,848.00 28.00 0.99% -18.07%
Vertex Pharmaceuticals 268.83 0.35 0.13% 29.99%
Xoma 17.44 0.18 1.04% -40.88%

Indexes Price Day Year
USND 11302 37.06 0.33% -17.74%
US2000 1782 16.94 0.96% -20.79%

Neurocrine Biosciences
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing, and delivering treatments for people with neurological, endocrine and psychiatric disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis, uterine fibroids, and clinical programs in multiple therapeutic areas. The Company's product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has two dosing options (40 milligram (mg) and 80 mg capsules). ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease. ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. ORIAHNN (elagolix, estradiol, and norethindrone acetate; elagolix) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.